Ask about this productRelated genes to: ASB12 antibody
- Gene:
- ASB12 NIH gene
- Name:
- ankyrin repeat and SOCS box containing 12
- Previous symbol:
- -
- Synonyms:
- FLJ39577
- Chromosome:
- Xq11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-12-03
- Date modifiied:
- 2016-10-05
Related products to: ASB12 antibody
Related articles to: ASB12 antibody
- Prostate cancer (PCa) exhibits significant genomic differences between Western and Asian populations. This study aimed to design a predictive model applicable across diverse populations while selecting a limited set of genes suitable for clinical implementation. - Source: PubMed
Publication date: 2025/01/28
Han FengxianFan XiaohuiLong PengweiZhang WenhuiLi QitingLi YingxuanGuo XingpengLuo YinranWen RongqiWang ShengZhang ShanLi YizhuoWang YanGao XuLi Jing - As a member of the Ankyrin repeat and SOCS box () family, the is enriched in the testes and highly conserved in multiple species. The knockout of the gene not significantly affect spermatogenesis, but led to a compensatory increase in the mRNA expression level of the . Although it has been reported that the is not required for spermatogenesis and male fertility in mice, the functional role of remains not to be clearly elucidated. - Source: PubMed
Publication date: 2025/07/31
Xu ChangtongQiu XiyaZheng AiyanPu YanWu TiantianDing JieZheng Bo - Exosomes encompass a great deal of valuable biological information and play a critical role in tumor development. However, the mechanism of exosomal lncRNAs remains poorly elucidated in bladder cancer (BCa). In this study, we identified exosomal lnc-TAF12-2:1 as a novel biomarker in BCa diagnosis and aimed to investigate the underlying biological function. Dual luciferase reporter assay, RNA immunoprecipitation (RIP), RNA pulldown assays, and xenograft mouse model were used to verify the competitive endogenous RNA mechanism of lnc-TAF12-2:1. We found exosomal lnc-TAF12-2:1 up-regulated in urinary exosomes, tumor tissues of patients, and BCa cells. Down-regulation of lnc-TAF12-2:1 impaired BCa cell proliferation and migration, and promoted cell cycle arrest at the G0/G1 phase and cell apoptosis. The opposite effects were also observed when lnc-TAF12-2:1 was overexpressed. lnc-TAF12-2:1 was transferred by intercellular exosomes to modulate malignant biological behavior. Mechanistically, lnc-TAF12-2:1 packaged in the exosomes relieved the miRNA-mediated silence effect on ASB12 via serving as a sponger of miR-7847-3p to accelerate progression in BCa. ASB12 was also first proved as an oncogene to promote cell proliferation and migration and depress cell cycle arrest and cell apoptosis in our data. In conclusion, exosomal lnc-TAF12-2:1, located in the cytoplasm of BCa, might act as a competitive endogenous RNA to competitively bind to miR-7847-3p, and then be involved in miR-7847-3p/ASB12 regulatory axis to promote tumorigenesis, which provided a deeper insight into the molecular mechanism of BCa. - Source: PubMed
Publication date: 2024/08/05
Chen SongCheng JieLiu ShuangtaiShan DanniWang TingWang Xinghuan - This retrospective cohort study evaluated the impact of nasal morbidity on quality of life following endoscopic endonasal skull base surgery (EESBS) using the Sino-Nasal Outcome Test-22 (SNOT-22) and Anterior Skull Base Inventory (ASB-12). While 89% of patients found the nasal morbidity acceptable given the surgical goals, limitations include the study's retrospective nature, specific focus on certain pathologies, and a short follow-up period of up to 6 months. Future research should utilize comprehensive outcome assessment tools and consider broader patient populations to enhance study validity and applicability. - Source: PubMed
Publication date: 2024/05/04
Zaidi Syeda Mahrukh Fatima - The endoscopic endonasal approach is more disruptive to normal anatomy (particularly nasal mucosa) than the transseptal submucosal microscopic approach. This may result in greater postoperative nasal morbidity, in turn reducing quality of life. We aimed to assess the severity and time course of nasal morbidity, and its impact on quality of life, following endoscopic endonasal skull base surgery in this retrospective cohort study. We identified 95 patients who underwent endoscopic endonasal skull base surgery for anterior skull base pathologies. Nasal-specific questions from the Sino-Nasal Outcome Test-22 (SNOT-22) and the Anterior Skull Base inventory (ASB-12) were combined with quality-of-life questions. Patient demographics, diagnosis, and operative data were collected from electronic records. Age of the cohort ranged from 14-83 years. Time elapsed since surgery ranged from 3-85 months. 85/95 (89%) felt that nasal morbidity associated with surgery was acceptable, given the underlying reason for, and outcome of surgery; 10/95 (11%) did not. 71/95 (75%) reported no change or improvement in olfaction 3-months following surgery. 24/95 (25%) reported a deterioration in olfaction which was mild in 7%, moderate in 7%, and severe in 11%. Nasal crusting, nasal obstruction, and headache were moderately problematic symptoms but improved significantly by 3-month follow-up. Nasal discharge, nasal pain, and nasal whistling were mildly problematic and improved significantly by 3-months. 62/95 (65%) patients reported 'no change' in day-to-day activities due to the effects on their nose after surgery. 19/95 (20%) had 'mild inconvenience', 8/95 (8%) 'moderate inconvenience' and 6/95 (6%) 'severe inconvenience'. Endoscopic anterior skull base surgery is associated with nasal morbidity. Whilst 35% of patients appreciate a consequent negative impact on day-to-day life, the overwhelming majority feel that nasal morbidity is acceptable, given the wider surgical goals. - Source: PubMed
Publication date: 2023/12/16
Hegde RutwikProdan VladFutera KarolinaHathorn IainGohil RohitHughes Mark A